



BD

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/55, 15/70, 9/18, A61K 37/64, C12N 1/21, C12P 21/08, G01N 33/573, C12Q 1/44		A1	(11) International Publication Number: WO 95/00649 (43) International Publication Date: 5 January 1995 (05.01.95)		
(21) International Application Number: PCT/GB94/01374		frey, Mark, Prouse [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). RICE, Simon, Quentyn, John [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB).			
(22) International Filing Date: 24 June 1994 (24.06.94)		(74) Agent: VALENTINE, Jill, Barbara; SmithKline Beecham plc, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).			
(30) Priority Data: 9313144.9 25 June 1993 (25.06.93) GB 9400413.2 11 January 1994 (11.01.94) GB		(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).			
(71) Applicant (<i>for all designated States except US</i>): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).		Published <i>With international search report.</i>			
(72) Inventors; and					
(75) Inventors/Applicants (<i>for US only</i>): MACPHEE, Colin, Houston [GB/GB]; SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Herts AL6 9AR (GB). TEW, David, Graham [GB/GB]; SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Herts AL6 9AR (GB). SOUTHAN, Christopher, Donald [GB/GB]; SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Herts AL6 9AR (GB). HICKEY, Deirdre, Mary, Bernadette [IE/GR]; SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Herts AL6 9AR (GB). GLOMER, Israel, Simon [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). LAWRENCE, Geof-					
(54) Title: LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A ₂ , INHIBITORS THEREOF AND USE OF THE SAME IN DIAGNOSIS AND THERAPY					
(57) Abstract					
The enzyme Lp-PLA ₂ in purified form, an isolated nucleic acid molecule encoding Lp-PLA ₂ , the use of an inhibitor of the enzyme Lp-PLA ₂ in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.					

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A₂, INHIBITORS THEREOF AND USE
OF THE SAME IN DIAGNOSIS AND THERAPY**

The present invention relates to the use of inhibitors of an enzyme in the therapy, in particular in the treatment of atherosclerosis. The present invention also 5 relates to the isolation and purification of the enzyme, to isolated nucleic acids encoding the enzyme, to recombinant host cells transformed with DNA encoding the enzyme, to the use of the enzyme in diagnosing a patient's susceptibility to atherosclerosis, and to the use of the enzyme in identifying compounds which are potentially useful for the treatment of atherosclerosis.

10 Lipoprotein Associated Phospholipase A₂ (Lp-PLA₂), also previously known in the art as Platelet Activating Factor Acetyl Hydrolase (PAF acetyl hydrolase). During the conversion of LDL to its oxidised form, Lp-PLA₂ is responsible for hydrolysing the sn-2 ester of oxidatively modified phosphatidylcholine to give lyso-phosphatidylcholine and an oxidatively modified fatty acid. Both of these products of Lp-PLA₂ action are potent chemoattractants for 15 circulating monocytes. As such, this enzyme is thought to be responsible for the accumulation of cells loaded with cholesterol ester in the arteries, causing the characteristic 'fatty streak' associated with the early stages of atherosclerosis. Inhibition of the Lp-PLA₂ enzyme would therefore be expected to stop the build up 20 of this fatty streak (by inhibition of the formation of lysophosphatidylcholine), and so be useful in the treatment of atherosclerosis. In addition, it is proposed that Lp-PLA₂ plays a direct role in LDL oxidation. This is due to the poly unsaturated fatty acid-derived lipid peroxide products of Lp-PLA₂ action contributing to and enhancing the overall oxidative process. In keeping with this idea, Lp-PLA₂ inhibitors inhibit LDL 25 oxidation. Lp-PLA₂ inhibitors may therefore have a general application in any disorder that involves lipid peroxidation in conjunction with the enzyme activity, for example in addition to conditions such as atherosclerosis and diabetes other conditions such as rheumatoid arthritis, stroke, myocardial infarction, reperfusion injury and acute and chronic inflammation.

30 The present invention therefore provides in a first aspect an inhibitor of the enzyme lipoprotein associated Lp-PLA₂ for use in therapy, in particular in the treatment of atherosclerosis. Suitable compounds able to inhibit the Lp-PLA₂ enzyme are known in the art and include for example, the following compounds of structure (I):



(I)

35

in which R is C₁₋₆alkylCONR²;

R² is hydrogen or C₁₋₆alkyl;

X is oxygen, sulphur or -O(CO)-;

5 R¹ is C₈₋₂₀alkyl;

Z is N(R³)₂, \oplus N(R³)₃, SR³, \oplus S(R³)₂, in which each group R³ is the same or different and is C₁₋₆ alkyl, OR², C₁₋₄alkanoyl, imidazolyl or N-methylimidazolyl

10 Suitably R² is hydrogen or C₁₋₆ alkyl; preferably R² is hydrogen.

Suitably X is oxygen, sulphur or -O(CO)-; preferably X is oxygen

Suitably R¹ is C₈₋₂₀alkyl; preferably R¹ is C₁₆₋₁₈ alkyl

Suitably Z is N(R³)₂, \oplus N(R³)₃, SR³, \oplus S(R³)₂, in which each group R³ is the same or different and is C₁₋₆ alkyl, OR², C₁₋₄alkanoyl, imidazolyl or N-methylimidazolyl; preferably Z is SR³ in which R³ is methyl or OR² in which R² is hydrogen

15 The compounds of structure (I) can be prepared by processes known to those skilled in the art, for example as described in J Chem Soc Chem Comm., 1993, 70-72; J Org Chem, 1983, 48, 1197 and Chem Phys Lipids, 1984, 35, 29-37 or procedures analogous thereto.

20 When used in therapy, the compounds of structure (I) are formulated in accordance with standard pharmaceutical practice.

The compounds of structure (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, 25 suspensions or emulsions, tablets, capsules and, lozenges.

A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.

30 A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.

35 A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.

Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.

A typical suppository formulation comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.

Preferably the composition is in unit dose form such as a tablet or capsule.

Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.

The daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 25 mg, of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day. Suitably the compounds will be administered for a period of continuous therapy.

The enzyme, lipoprotein associated Lp-PLA₂ has not hitherto been available in isolated purified form. The present invention therefore provides in a further aspect, the enzyme lipoprotein associated Lp-PLA₂ in purified form. By purified form is meant at least 80%, more preferably 90%, still more preferably 95% and most preferably 99% pure with respect to other protein contaminants.

The enzyme Lp-PLA₂ may be characterised by one or more partial peptide sequences selected from SEQ ID NOs:1, 2, 3, 4, 10 and 11 or by the partial peptide sequence comprising residues 271 to 441 or consisting of residues 1 to 441 of SEQ ID NO:9. The enzyme Lp-PLA₂ may further or alternatively characterised by its molecular weight found to be 45kDa, at least 45kDa, 45-47kDa, 46-47kDa or 45-50kDa.

The invention also provides fragments of the enzyme having Lp-PLA₂ activity.

The enzyme can be isolated and purified using the methods hereafter described. Once isolated, the protein sequence of the enzyme can be obtained using standard techniques. In identifying said sequence, a number of protein fragments have been identified, each of which comprises part of the whole sequence of the

enzyme. These sequences are themselves novel and form a further aspect of the invention.

This invention also provides isolated nucleic acid molecules encoding the enzyme, including mRNAs, DNAs, cDNAs as well as antisense analogs thereof and 5 biologically active and diagnostically or therapeutically useful fragments thereof.

In particular, the invention provides an isolated nucleic acid molecule consisting of bases 1 to 1361 or 38 to 1361 or comprising the sequence corresponding to bases 848 to 1361 of SEQ ID NO: 9.

This invention also provides recombinant vectors, such as cloning and 10 expression plasmids useful as reagents in the recombinant production of the enzyme, as well as recombinant prokaryotic and/or eukaryotic host cells comprising the novel nucleic acid sequence.

This invention also provides nucleic acid probes comprising nucleic acid 15 molecules of sufficient length to specifically hybridize to the novel nucleic acid sequences.

This invention also provides an antisense oligonucleotide having a sequence capable of binding with mRNAs encoding the enzyme so as to prevent the translation of said mRNA.

This invention also provides transgenic non-human animals comprising a 20 nucleic acid molecule encoding the enzyme. Also provided are methods for use of said transgenic animals as models for mutation and SAR (structure/activity relationship) evaluation as well as in drug screens.

This invention further provides a method of screening compounds to identify those compounds which inhibit the enzyme comprising contacting isolated enzyme 25 with a test compound and measuring the rate of turnover of an enzyme substrate as compared with the rate of turnover in the absence of test compound.

"Recombinant" polypeptides refer to polypeptides produced by recombinant DNA techniques; i.e., produced from cells transformed by an exogenous DNA construct encoding the desired polypeptide. "Synthetic" polypeptides are those 30 prepared by chemical synthesis.

A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication in vivo; i.e., capable of replication under its own control.

A "vector" is a replicon, such as a plasmid, phage, or cosmid, to which 35 another DNA segment may be attached so as to bring about the replication of the attached segment.

A "double-stranded DNA molecule" refers to the polymeric form of deoxyribonucleotides (bases adenine, guanine, thymine, or cytosine) in a double-stranded helix, both relaxed and supercoiled. This term refers only to the primary and

secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may 5 be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the sense strand of DNA.

A DNA "coding sequence of" or a "nucleotide sequence encoding" a particular protein, is a DNA sequence which is transcribed and translated into a polypeptide when placed under the control of appropriate regulatory sequences.

- 10 A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. Within the promoter sequence will be found a transcription initiation site (conveniently defined by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.
- 15 Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT" boxes.

- 20 DNA "control sequences" refers collectively to promoter sequences, ribosome binding sites, polyadenylation signals, transcription termination sequences, upstream regulatory domains, enhancers, and the like, which collectively provide for the expression (i.e., the transcription and translation) of a coding sequence in a host cell.

- 25 A control sequence "directs the expression" of a coding sequence in a cell when RNA polymerase will bind the promoter sequence and transcribe the coding sequence into mRNA, which is then translated into the polypeptide encoded by the coding sequence.

A "host cell" is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous DNA sequence.

- 30 A cell has been "transformed" by exogenous DNA when such exogenous DNA has been introduced inside the cell membrane. Exogenous DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. In prokaryotes and yeasts, for example, the exogenous DNA may be maintained on an episomal element, such as a plasmid. With respect to eukaryotic cells, a stably transformed or transfected cell is one in which the exogenous DNA has become integrated into the chromosome so that it is inherited by daughter cells
- 35 through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cell containing the exogenous DNA.

A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth *in vitro* for many generations.

Two DNA or polypeptide sequences are "substantially homologous" or "substantially the same" when at least about 85% (preferably at least about 90%, and most preferably at least about 95%) of the nucleotides or amino acids match over a defined length of the molecule and includes allelic variations. As used herein, substantially homologous also refers to sequences showing identity to the specified DNA or polypeptide sequence. DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., "Current Protocols in Mol. Biol." Vol. I & II, Wiley Interscience. Ausbel *et al.* (ed.) (1992). Protein sequences that are substantially the same can be identified by proteolytic digestion, gel electrophoresis and microsequencing.

The term "functionally equivalent" intends that the amino acid sequence of the subject protein is one that will exhibit enzymatic activity of the same kind as that of Lp-PLA₂.

A "heterologous" region of a DNA construct is an identifiable segment of DNA within or attached to another DNA molecule that is not found in association with the other molecule in nature.

This invention provides an isolated nucleic acid molecule encoding the enzyme Lp-PLA₂. One means for isolating the coding nucleic acid is to probe a human genomic or cDNA library with a natural or artificially designed probe using art recognized procedures (See for example: "Current Protocols in Molecular Biology", Ausubel, F.M., et al. (eds.) Greene Publishing Assoc. and John Wiley Interscience, New York, 1989, 1992); for example using the protein fragment information disclosed herein. The enzyme of this invention may be made by recombinant genetic engineering techniques. The isolated nucleic acids particularly the DNAs can be introduced into expression vectors by operatively linking the DNA to the necessary expression control regions (e.g. regulatory regions) required for gene expression. The vectors can be introduced into the appropriate host cells such as prokaryotic (e.g., bacterial), or eukaryotic (e.g. yeast, insect or mammalian) cells by methods well known in the art (Ausubel *et al.*, *supra*). The coding sequences for the desired proteins having been prepared or isolated, can be cloned into a suitable vector or replicon. Numerous cloning vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of choice. Examples of recombinant DNA vectors for cloning and host cells which they can transform include the bacteriophage λ (*E. coli*), pBR322 (*E. coli*), pACYC177 (*E. coli*),

pKT230 (gram-negative bacteria), pGV1106 (gram-negative bacteria), pLAFR1 (gram-negative bacteria), pME290 (non-*E. coli* gram-negative bacteria), pHV14 (*E. coli* and *Bacillus subtilis*), pBD9 (*Bacillus*), pIJ61 (*Streptomyces*), pUC6 (*Streptomyces*), YIp5 (*Saccharomyces*), a baculovirus insect cell system, , YCp19 (Saccharomyces). See, generally, "DNA Cloning": Vols. I & II, Glover et al. ed. IRL Press Oxford (1985) (1987) and; T. Maniatis et al. ("Molecular Cloning" Cold Spring Harbor Laboratory (1982).

The gene can be placed under the control of a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator (collectively referred to herein as "control" elements), so that the DNA sequence encoding the desired protein is transcribed into RNA in the host cell transformed by a vector containing this expression construction. The coding sequence may or may not contain a signal peptide or leader sequence. The protein sequences of the present invention can be expressed using, for example, the *E. coli* tac promoter or the protein A gene (spa) promoter and signal sequence. Leader sequences can be removed by the bacterial host in post-translational processing. See, e.g., U.S. Patent Nos. 4,431,739; 4,425,437; 4,338,397.

In addition to control sequences, it may be desirable to add regulatory sequences which allow for regulation of the expression of the protein sequences relative to the growth of the host cell. Regulatory sequences are known to those of skill in the art, and examples include those which cause the expression of a gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Other types of regulatory elements may also be present in the vector, for example, enhancer sequences.

An expression vector is constructed so that the particular coding sequence is located in the vector with the appropriate regulatory sequences, the positioning and orientation of the coding sequence with respect to the control sequences being such that the coding sequence is transcribed under the "control" of the control sequences (i.e., RNA polymerase which binds to the DNA molecule at the control sequences transcribes the coding sequence). Modification of the coding sequences may be desirable to achieve this end. For example, in some cases it may be necessary to modify the sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the reading frame. The control sequences and other regulatory sequences may be ligated to the coding sequence prior to insertion into a vector, such as the cloning vectors described above. Alternatively, the coding sequence can be cloned directly into an expression vector which already contains the control sequences and an appropriate restriction site. Modification of the coding sequences may also be performed to alter codon usage to suit the chosen host cell, for enhanced expression.

- In some cases, it may be desirable to add sequences which cause the secretion of the polypeptide from the host organism, with subsequent cleavage of the secretory signal. It may also be desirable to produce mutants or analogs of the enzyme of interest. Mutants or analogs may be prepared by the deletion of a portion 5 of the sequence encoding the protein, by insertion of a sequence, and/or by substitution of one or more nucleotides within the sequence. Techniques for modifying nucleotide sequences, such as site-directed mutagenesis, are well known to those skilled in the art. See, e.g., T. Maniatis et al., *supra*; DNA Cloning, Vols. I and II, *supra*; Nucleic Acid Hybridization, *supra*.
- 10 A number of prokaryotic expression vectors are known in the art. See, e.g., U.S. Patent Nos. 4,578,355; 4,440,859; 4,436,815; 4,431,740; 4,431,739; 4,428,941; 4,425,437; 4,418,149; 4,411,994; 4,366,246; 4,342,832; see also U.K. Patent Applications GB 2,121,054; GB 2,008,123; GB 2,007,675; and European Patent Application 103,395. Yeast expression vectors are also known in the art. See, e.g.,
- 15 U.S. Patent Nos. 4,446,235; 4,443,539; 4,430,428; see also European Patent Applications 103,409; 100,561; 96,491. pSV2neo (as described in J. Mol. Appl. Genet. 1:327-341) which uses the SV40 late promoter to drive expression in mammalian cells or pCDNA1neo, a vector derived from pCDNA1(Mol. Cell Biol. 7:4125-29) which uses the CMV promoter to drive expression. Both these latter two
- 20 vectors can be employed for transient or stable(using G418 resistance) expression in mammalian cells. Insect cell expression systems, e.g., Drosophila, are also useful, see for example, PCT applications US 89/05155 and US 91/06838 as well as EP application 88/304093.3.

Depending on the expression system and host selected, the enzyme of the 25 present invention may be produced by growing host cells transformed by an expression vector described above under conditions whereby the protein of interest is expressed. The protein is then isolated from the host cells and purified. If the expression system secretes the protein into growth media, the protein can be purified directly from the media. If the protein is not secreted, it is isolated from cell lysates 30 or recovered from the cell membrane fraction. Where the protein is localized to the cell surface, whole cells or isolated membranes can be used as an assayable source of the desired gene product. Protein expressed bacterial hosts such as E. coli may require isolation from inclusion bodies and refolding. The selection of the appropriate growth conditions and recovery methods are within the skill of the art.

35 The identification of this novel target for the treatment of atherosclerosis, also leads to a novel diagnostic method to diagnose a patient's susceptibility to developing atherosclerotic disease.

The present invention therefore provides in a still further aspect a diagnostic method comprising isolating a sample of blood from the patient, and assaying said


sample for Lp-PLA₂ activity. Patients that are susceptible to atherosclerotic disease are expected to have elevated levels of the Lp-PLA₂ enzyme, and hence the levels of Lp-PLA₂ provides an indication of the patient's susceptibility to atherosclerotic disease. Moreover, Lp-PLA₂ is found located predominantly on dense subfraction(s) 5 of LDL which are known to be very atherogenic. Plasma Lp-PLA₂ levels could therefore provide a ready measure of these very atherogenic small dense LDL particles.

It is expected that the presence of the enzyme in the blood sample of the patient can be assayed by analysis of enzyme activity (i.e. by an assay set up against 10 the purified enzyme as standard); or alternatively by assaying protein content of the sample by using polyclonal or monoclonal antibodies prepared against the purified enzyme. Monoclonal (and polyclonal) antibodies raised against the purified enzyme or fragments thereof are themselves novel and form a further aspect of the invention.

DATA AND EXAMPLES

1. Screen for Lp-PLA₂ inhibition.

Enzyme activity was determined by measuring the rate of turnover of the
 5 artificial substrate (A) at 37 °C in 50mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid) buffer containing 150mM NaCl, pH 7.4.





10 Assays were performed in 96 well titre plates.

Lp-PLA₂ was pre-incubated at 37 °C with vehicle or test compound for 10 min in a total volume of 180 µl. The reaction was then initiated by the addition of 20 µl 10x substrate (A) to give a final substrate concentration of 20 µM. The reaction was followed at 405 nm for 20 minutes using a plate reader with automatic mixing.

15 The rate of reaction was measured as the rate of change of absorbance.

RESULTS:

Compound No	XR ¹	R	Z	IC ₅₀ (µM)
1	O(CH ₂) ₁₅ CH ₃	CH ₃ CONH	N ⁺ (CH ₃) ₃	0.8
2	O(CH ₂) ₁₇ CH ₃	CH ₃ CONH	N ⁺ (CH ₃) ₃	3.5
3	O(CH ₂) ₁₇ CH ₃	CH ₃ CONH	S ⁺ (CH ₃) ₂	1.0
4	O(CH ₂) ₁₇ CH ₃	CH ₃ CONH	SCH ₃	0.08

Compound No	XR ¹	R	Z	IC ₅₀ (μM)
5	O(CH ₂) ₁₇ CH ₃	CH ₃ CONH	OH	0.45
6	O(CH ₂) ₁₇ CH ₃	CH ₃ CONH	OAc	0.2
7	O(CH ₂) ₁₇ CH ₃	CH ₃ CONH		0.5
8	O(CH ₂) ₁₇ CH ₃	CH ₃ CONH		0.55
9	O(CH ₂) ₁₇ CH ₃	CF ₃ CONH	N ⁺ (CH ₃) ₃	2.5

2. Copper Stimulated LDL Oxidation:

5 Copper stimulated oxidation of LDL is routinely measured by following the increase in conjugated diene formation by monitoring the change in absorption at 234 nm. This assay can be used to study inhibitors of oxidative modification of LDL. Figure 1 demonstrates that Lp-PLA₂ inhibitors are effective inhibitors of LDL oxidation through a prolongation of the lag phase, using compound 4 as an example.

10 3. Inhibition of Cu²⁺ stimulated lyso-phosphatidylcholine (lyso-PtdCho) formation.

15 A 1 ml aliquot of human LDL (0.25mg protein/ml) was incubated for 15 min at 37 °C with compound or vehicle. 5 μM Cu²⁺ was then added to allow oxidation/lyso-PtdCho formation to occur. The incubation was terminated by the addition of 3.75 ml chloroform/methanol/c HCl (200:400:5,v/v/v). Following the addition of 1.25 ml chloroform and 1.25 ml 0.1M HCl, the mixture was vortexed and centrifuged. The lower phase was carefully removed and the upper phase re-extracted with an equal volume of synthetic lower phase. The extracts were pooled and dried under nitrogen.

20 Phospholipids were reconstituted into 50 μl chloroform/methanol (2:1 v/v). 10 μl aliquots were spotted on to pre-run silica gel HPTLC plates and then developed in chloroform/methanol 25-30% methylamine (60:20:5 v/v/v). Plates were subsequently sprayed with the fluorescent indicator, 2-p-toluidinylnaphthalene-6-sulphonic acid (1 mM in 50 mM Tris/HCl, pH 7.4) to identify phospholipid components. Fluorescence was measured at 222nm using a CAMAG TLC scanner.

Lipoprotein lyso-PtdCho content was quantified using a standard curve (0.05-0.5 μ g) prepared in parallel.

Compound 4 dose dependently inhibits LDL lyso-PtdCho accumulation stimulated by copper ions with an IC₅₀ value of ~30 μ M.

5

4. Purification of lipoprotein associated Lp-PLA₂

Low density lipoprotein (LDL) was obtained by plasma apheresis. The LDL was dialysed against 0.5 M NaCl, 50 mM MES (4-morpholine ethane sulphonic acid), pH = 6.0 overnight at 4°C. Solid CHAPS (3-[(-3-cholamidopropyl)dimethylamino]-1-propane sulphonate) was added to 10 mM and the LDL stirred for 30 minutes to effect solubilisation. The solubilised LDL was pumped onto a pre-equilibrated Blue Sepharose 6FF (Pharmacia) column (2.6 x 20 cm). The column was then washed with 50 mM MES, 10 mM CHAPS, 0.5 M NaCl, pH = 6.0 followed by 50 mM Tris, 10 mM CHAPS, 0.5 M NaCl, pH = 8.0 until the absorbance (280 nm) of the eluate reached zero. Lp-PLA₂ was eluted using 50 mM Tris, 10 mM CHAPS, 1.5 M NaCl, pH = 8.0. The Lp-PLA₂ fraction was then concentrated and dialysed overnight against 50 mM Tris, 10 mM CHAPS, pH = 8.0.

The dialysed Lp-PLA₂ was submitted to anion exchange chromatography on a mono Q column (Pharmacia) using 50 mM Tris, 10 mM CHAPS, pH = 8.0 with a NaCl gradient from zero to 0.3 M. The Lp-PLA₂ fractions obtained from the mono Q column were applied directly to a Hi Trap Blue cartridge (Pharmacia). The cartridge was washed with 50 mM Tris, 10 mM CHAPS, 0.5 M NaCl, pH = 8.0 until the absorbance of the eluate (280 nm) was zero. Lp-PLA₂ was then eluted using 50 mM Tris, 10 mM CHAPS, 1.5 M NaCl, pH = 8.0. This gave Lp-PLA₂ which is greater than 95% pure as shown in Figure 2. This also demonstrates that the native enzyme is extensively glycosylated.

5. Enzyme Sequence

The purity of the final enzyme preparation was verified by five criteria 1) SDS-polyacrylamide gel electrophoresis gave one band for both native and de-glycosylated forms. 2) Reverse phase high pressure liquid chromatography (RP-HPLC) gave a single peak, 3) The intact preparation gave no results by protein sequencing, implying that the protein was N-terminally blocked and free of any contaminants with open N-terminals, 4) By laser desorption mass spectrometry only one broad peak was observed with de-glycosylated protein, and 5) none of the sections of extended peptide data from sequencing gave any database matches indicative of contaminating proteins. Three cleavage strategies were used to obtain internal sequence information; trypsin (after de-glycosylation), cyanogen bromide (methionine cleavage) and BNPS-Skatol (tryptophan cleavage). The resulting

peptides were separated by RP-HPLC, collected and sequenced. The accumulated sequence data allowed several extended stretches of primary structure of the Lp-PLA₂ enzyme to be verified. These are shown below as Peptides 1, 2, 3 and 4 (SEQ ID Nos 1 to 4). When searched against the National Centre for Biotechnological information (NCBI) non-redundant peptide sequence databases no high similarity matches were obtained. Estimation of the molecular weight of pure, de-glycosylated protein by laser desorption mass spectrometry gives values in the region of 45-47kDa (separately 45kDa and 46-47kDa), indicating that the sequences constitute approximately 15 to 20% of the protein.

10

6. Gene Sequence

Three expressed sequence tags (EST's) from human cDNA libraries have been found to have extensive alignments with the Peptide Sequences 1 to 3. These EST's are shown below as Nucleotide Sequences 1 to 3 (SEQ ID Nos: 5 to 7)

15 Nucleotide Sequence 1 is a 420 base sequence derived from a human foetal spleen library. Nucleotide Sequence 2 is a 379 base sequence derived from a 12-week human embryo library. Nucleotide Sequence 3 is a 279 base sequence derived from a T-cell lymphoma library. The identities at both the nucleic acid and amino acid level justified an overlapping alignment of the cDNA of all three ESTs, Nucleotide Sequences 3 (bases 1-278), 1 (bases 1-389) (in reverse orientation) and 2 (bases 1-304) with the Peptide Sequences 1, 2 and 3 (partially). Beyond these limits, the poor resolution of the raw sequence data precludes accurate base calling.

20

There are two remaining unassigned peptide sections from Peptides 3 and 4, both of which are expected to be present in the complete protein, -Q-Y-I-N-P-A-V-, and W-L-M-G-N-I-L-R-L-L-F-G-S-M-T-T-P-A-N-.

25

7. Isolation of full-length Lp-PLA₂ cDNA

The full DNA sequence was determined for the clone (HLTA145) from which the Lymphoma EST (SEQ ID No:7) was derived, giving a total of 572 bases; SEQ ID No:8. There is one base difference between this sequence and the EST (between bases 1 to 256 of the EST); at position 27 of HLTA145 there is an A compared with a T in the EST. This would cause a coding change; L in HLTA145 compared with F in the EST. Clone HLTA145 was used as a radiolabelled probe to screen the Lymphoma cDNA library in order to isolate the full-length Lp-PLA₂ clone. The library was prepared in the bacteriophage λ vector, Unizap XR (Stratagene).

Preparation of the filters for screening

- The library was plated out at a density of 20,000 plaques per 150mm petri dish onto *E.coli* XL-1 Blue host cells (ie. 200,000 plaques on 10 dishes). An overnight of XL-1 Blue was prepared in 100mls LB/0.2%w/v Maltose/10mM MgSO₄.
- 5 The cells were pelleted, resuspended in 50mls 10mM MgSO₄ and stored on ice. 180µl of the library bacteriophage stock (23,400 pfu's) were added to 7mls XL-1 Blue cells, mixed and divided into 10 aliquots of 615µl. The 10 tubes were incubated at 37°C for 30 minutes. 7mls of molten (@45°C) top agarose (0.7%w/v agarose in LB) were added, mixed well and poured onto 150mm LB agar plates (1.5%w/v agar in LB).
- 10 The plates were inverted and incubated at 37°C for approximately 7.5 hours. The plates were held at 4°C until needed.

The plaques were transferred to 132mm Hybond-N nylon filters (Amersham International) by laying the filters on the plates for 2 minutes (4 minutes for the duplicate). The DNA's on the filters were denatured for 2 minutes (0.5M NaCl, 1.5M NaOH), neutralised for 4 minutes (1.5M NaCl, 1.0M Tris pH7.4) and the filters placed on 2 x SSC for 1 minute. The filters were then dried and the DNA cross-linked to the filter using a Stratalinker UV 2400 (Stratagene) at 120,000 µJoules/cm².

- 15 The filters were pre-hybridised in 1mM EDTA, 0.5M NaHPO₄, 7%SDS (Church,GM. and Gilbert,W. (1984) PNAS USA 81 p1991-1995) in a Techne HB2 hybridisation oven at 55°C for 3 hours. Each bottle contained 2 filters and 25mls prehybridization solution.

Preparation of the radiolabelled probe

- 20 The probe cDNA (from HLTA 145) was excised from pBluescript II SK+/- as an approximately 600bp EcoRI-XhoI fragment and approximately 100ng of gel purified fragment were labelled using 1.2MBq ³²P dATP and 1.2MBq ³²P dCTP by PCR labelling using Taq DNA polymerase (Boehringer Mannheim) and primers designed to prime at the 5' and 3' ends of the EST sequence. The labelling reaction was carried out in a total volume of 200µl and included unlabelled dNTP's at the
- 25 following concentrations:-

dATP	20µM
dCTP	20µM
dGTP	200µM
dTTP	200µM

30

The PCR reaction was carried out over 35 cycles of:-

94°C for 30s

60°C for 30s

72°C for 30s

Screening

The radiolabelled probe was denatured at 98°C for 5 minutes and divided into 10 aliquots of 20µl. One aliquot was added per hybridisation bottle.

- 5 Hybridisation was carried out over 16 hours at 55°C. The filters were washed at 60°C (2 x 10minutes) with 0.1%w/v SDS, 0.1xSSC (50mls per wash per bottle). The filters were autoradiographed and the films (Fuji Medical X-Ray Film) developed after 5 days exposure.

- Duplicate positives were progressed to a secondary screen. The plaques
10 were cored out into 1ml SM (100mM NaCl, 10mM MgSO₄, 1M Tris, pH7.4), titrated and plated onto 90mm petri dishes at between 20 and 200 pfu's per dish. The secondary screen was carried out as described for the primary screen except the filters were washed at 65°C. The autoradiographs were developed after 16 hours exposure.

15 **DNA sequencing**

- The duplicated positive clones from the secondary screen were excised from the λ Unizap XR bacteriophage vector into the Bluescript phagemid (according to the Stratagene manual) for characterisation. One of the clones, carrying an insert of approximately 1.5kb, was sequenced on both strands (using the USB Sequenase 2.0 DNA sequencing kit) by primer walking (SEQ ID No:9). The cDNA has an open reading frame with the potential to code for a polypeptide of 441 amino acids.

The 3' region of the full-length cDNA aligns with the HLTA145 sequence with the exception of 3 mismatches (see below). The predicted polypeptide sequence of the lymphoma Lp-PLA₂ is shown as SEQ ID No:9.

- 25 Inspection of the full length cDNA (SEQ ID No: 9) reveals probable errors in Peptide 3. One of these errors is in the assignment of continuity between V-M which is incompatible with the perfect sequence match with the cDNA after this position. It seems likely that a short peptide, containing the sequence -Q-Y-I-N-P-, co-purified with the longer cyanogen bromide partial cleavage peptide and, by being present in greater quantity, was assigned as the major sequence and contiguous with the subsequent amino acids. The remaining section of Peptide 3 and the whole of Peptide 4 can be identified in the predicted full length enzyme sequence (SEQ ID No:9). It thus seems likely that Peptide 3 is in fact two separate Peptides 5 (SEQ ID No:10) and 6 (SEQ ID No:11). The second probable error has occurred in the transcription from the raw data for Peptide 3 which on checking was consistent with Peptide 5 having the sequence -Q-Y-I-N-P-V-A, rather than Q-Y-I-N-P-A-V-.
- 35 The 3 base differences are as follows:-

1) T at 859 is A in HLTA145; aminoacid change F in full-length, L in
HLTA145. (Note that the original EST is identical with the full-length
cDNA at position 859).

2) C at 1173 is T in HLTA145; aminoacid change A in full-length, V in
5 HLTA145.

3) T at 1203 is C in HLTA145; aminoacid change L in full-length, S in
HLTA145.

The peptide data and the Foetal Spleen EST sequence (SEQ ID No:5)
support the full-length cDNA sequence for differences (2) and (3) although the
10 Human Embryo EST (SEQ ID No:6) is identical to the Lymphoma EST (SEQ ID
No:7) at position 1173. The Human Embryo EST (SEQ ID No:6) has a further
difference (4) corresponding to position 1245 in the full-length Lymphoma sequence
(SEQ ID No:9)(comparison between bases 2 to 304 of the Human Embryo EST and
the full-length Lymphoma cDNA).

15 4) A at 1245 is T in the Embryo EST (SEQ ID No:6)(amino acid change D to V
in the Embryo EST). Peptide data covering this region supports the
Lymphoma DNA sequence (SEQ ID No:9).

The Lp-PLA₂ DNA sequence from 848 to 1361 of SEQ ID No:9 (amino acid
residues 271 to 441 of SEQ ID No:9) is the region for which all major data sets agree
20 substantially, ie. the peptide data, the Foetal spleen, full-length Lymphoma and it
includes the known active site and is therefore believed to be a significant
characterising region for the Lp-PLA₂ enzyme.

The predicted MW for the full reading frame is 50090. This is in excess of
that determined for the de-glycosylated, purified protein but post-translational events
25 could account for this discrepancy. The most likely of these are the removal of an N-
terminal signal peptide and/or limited proteolytic degradation of the protein C-
terminal. The latter could occur in-vivo, during purification, or under the conditions
of de-glycosylation.

30 DIAGNOSTIC METHOD

A sample of blood is taken from a patient, the plasma/serum sample prepared
and passed through a dextran sulphate column pre-equilibrated with 0.9% (w/v) NaCl
solution. Following washes with the same salt solution Lp-PLA₂ is eluted with a
4.1% (w/v) NaCl solution. Heparin agarose columns can also be used with the wash
35 and elution solutions containing 0.7% and 2.9% NaCl, respectively. Enzyme present
in the sample is determined by assaying for either

(a) enzyme activity:

The substrate (A) (see structure in 1) is used to assay Lp-PLA₂ activity by
monitoring the absorbance change at 400 nm. Purified enzyme is pre-incubated at

37°C and substrate (50 µM) is added after 5 minutes. The absorbance change at 400 nm is monitored for 20 minutes. This substrate has previously been reported as a substrate for classical calcium-dependent PLA₂s. (Washburn, W.N. and Dennis, E.A., J.Amer Chem.Soc., 1990, 112, 2040-2041); or

5 (b) protein content

Total protein content (i.e. enzyme content) can be determined using polyclonal antiserum raised against purified human Lp-PLA₂. The antisera recognises both native and glycosylated enzyme as measured by immunoprecipitation of activity and Western Blot analysis.

10 Polyclonal antiserum was prepared as follows. Immunisation of rabbits involved mixing 0.5 ml of purified human Lp-PLA₂ (=100µg) with an equal volume of Freund's complete adjuvant. The final emulsion was given subcutaneously in 4 X 0.25 ml injections. Boosting using a Freund's incomplete adjuvant\antigen mixture (4 X 0.25 ml subcut.; dosage = 50 µg) took place 4 weeks later. Adequate titre was
15 evident at between 6-8 weeks from initial injection.

IN THE FIGURES:

Fig. 1 is a graph of absorbance at 234 nm against time (min) in a study of inhibition of copper (5µM)- stimulated LDL (150µg/ml) oxidation by compound 4 vs
20 control vehicle.

Fig. 2 is an analysis the purified Lp-PLA₂ material of Example 4 following separation by polyacrylamide gel electrophoresis. Lanes 2, 4 and 6 contain adjacent fractions of purified native Lp-PLA₂. Lanes 1, 3 and 5 are fractions 2, 4 and 6 respectively after N-deglycosylation.

25

Sequence Data:

SEQ. ID. No: 1 -Peptide 1

-M-L-K-L-K-G-D-I-D-S-N-A-A-I-D-L-S-N-K-A-S-L-A-F-L-Q-K-H-L-G-L-H-K-D-F-D-Q-

30

SEQ. ID. No: 2 - Peptide 2

-W-M-F-P-L-G-D-E-V-Y-S-R-I-P-Q-P-L-F-F-I-N-S-E-Y-F-Q-Y-P-A-N-

SEQ. ID. No: 3 - Peptide 3

35

-Q-Y-I-N-P-A-V-M-I-T-I-R-G-S-V-H-Q-N-F-A-D-F-T-F-A-T-G-

SEQ. ID. No: 4 - Peptide 4

-W-L-M-G-N-I-L-R-L-L-F-G-S-M-T-T-P-A-N

SEQ. ID. No: 5 - Nucleotide Sequence 1

1 AAAAAACCTA TTTTAATCCT AATTGTATTT CTCTATTCCCT GAAGAGTTCT
 51 GTAACATGAT GTGTTGATTG GTTGTGTTAA TGTTGGTCCC TGGAAATAAGA
 101 TTCTCATCAT CTCCTTCAAT CAAGCAGTCC CACTGATCAA AATCTTTATG
 5 151 AAGTCCTAAA TGCTTTGTA AGAATGCTAA TGAAGCTTTG TTGCTAAGAT
 201 CAATAGCTGC ATTTGAATCT ATGTCTCCCT TTAATTGAG CATGTGTCCA
 251 ATTATTTTGC CAGTNGCAAA AGTGAAGTCA GCAAAATTCT GGTGGACTGA
 301 ACCCCTGATT GTAATCATCT TTCTTCTTT ATCAGGTGAG TAGCATTNTT
 351 TCATTTTAT GATATTAGCA GGATATTGGA AATATTCAAGN GTTGNTAAAA
 10 401 AGNGGNGGCT GAGGGATTCT

SEQ. ID. No: 6 - Nucleotide Sequence 2

1 TGCTAATATC ATAAAAATGTA AAAAATGCTA CTCACCTGAT AAAGAAAGAA
 51 AGATGATTAC AATCAGGGGT TCAGTCCACC AGANTTTGC TGACTTCACT
 15 101 TTTGCAACTG GCAAAATAAT TGGACACATG CTCAAATTAA AGGGAGACAT
 151 AGATTCAAAT GTAGCTATTG ATCTTAGCAA CAAAGCTTCA TTAGCATTCT
 201 TACAAAAGCA TTTAGGACTT CATAAAGATT TTGTTCAGTG GGAUTGCTTG
 251 ATTGAAGGAG ATGATGAGAA TCTTATTCCA GGGACCAACA TTAACACAAAC
 301 CAATTCAACA CATCATGTTT ACAGAACTTC TTCCAGGGAA TAGGAGGAAA
 20 351 TACAATTGGG GTTTAAAATA GGTTTTTTT

SEQ. ID. No: 7 - Nucleotide Sequence 3

1 GAAGAATGCA TTAGATTTAA AGTTTGATAT GGAACAACTG AAGGACTCTA
 51 TTGATAGGGA AAAAATAGCA GTAATTGGAC ATTCTTTGG TGGAGCAACG
 25 101 GTTATTCAAGA CTCTTAGTGA AGATCAGAGA TTCAGATGTG GTATTGCCCT
 151 GGATGCATGG ATGTTTCCAC TGGGTGATGA AGTATATTCC AGAATTCCCTC
 201 AGCCCCCTTT TTTTATCAAC TCTGAATATT TCCAATATCC TGCTAATATC
 251 ATAAAANTGG AAAAATGCTA CTCACCTGG

30 Seq.ID.No:8 - DNA sequence of HLTA145

	10	20	30	40	50
	AAAATAGCAG TAATTGGACA TTCTTTAGGT GGAGCAACGG TTATTCAAGAC				
	60	70	80	90	100
35	TCTTAGTGAA GATCAGAGAT TCAGATGTGG TATTGCCCTG GATGCATGGA				
	110	120	130	140	150
	TGTTTCCACT GGGTGATGAA GTATATTCCA GAATTCCCTCA GCCCCTCTTT				
	160	170	180	190	200
40	TTTATCAACT CTGAATATT CCAATATCCT GCTAATATCA TAAAAATGAA				

	210	220	230	240	250
	AAAATGCTAC TCACCTGATA AAGAAAGAAA GATGATTACA ATCAGGGTT				
5	260	270	280	290	300
	CAGTCACCA GAATTTGCT GACTTCACCTT TTGCAACTGG CAAAATAATT				
	310	320	330	340	350
	GGACACATGC TCAAATTAAA GGGAGACATA GATTCAAATG TAGCTATTGA				
10	360	370	380	390	400
	TCTTAGCAAC AAAGCTTCAT CAGCATTCTT ACAAAAGCAT TTAGGACTTC				
	410	420	430	440	450
	ATAAAAGATT TGATCAGTGG GACTGCTTGA TTGAAGGAGA TGATGAGAAT				
15	460	470	480	490	500
	CTTATTCCAG GGACCAACAT TAACACAACC AATCAACACA TCATGTTACA				
20	510	520	530	540	550
	GAACTCTCA GGAATAGAGA AATACAATTA GGATTAAAAT AGGTTTTTA				
	560	570			
	AAAAAAAAAA AAAAAAAACT CG				

25

SEQ. ID. No:9 - cDNA Sequence of Lymphoma Lp-PLA₂

	10	20	30	40	50
	TGAGAGACTAACGCTGAAACTGCTGCTCAGCTCCCAGATGGTGCCACCCA				
30	M	V	P	P	K
	60	70	80	90	100
	AATTGCATGTGCTTTCTGCCTCTGCGGCTGCCCTGGCTGTGGTTATCCT				
	L	H	V	L	F
	C	L	C	G	C
	A	V	V	Y	P
35	110	120	130	140	150
	TTTGACTGGCAATACATAAAATCCTGTTGCCATATGAAATCATCAGCATG				
	F	D	W	Q	Y
	I	N	P	V	A
	H	M	K	S	S
	A	W			
40	160	170	180	190	200
	GGTCAACAAAATACAAGTACTGATGGCTGCTGCAAGCTTGGCCAAACTA				
	V	N	K	I	Q
	Q	V	L	M	A
	A	A	A	S	F
	A	S	F	G	Q
	T	K	Q	T	K
45	210	220	230	240	250
	AAATCCCCGGGGAAATGGGCCTTATTCCGTTGGTACAGACTTAATG				
	I	P	R	G	N
	G	P	Y	S	V
	A	T	L	R	G
	L	Y	Y	P	S
	Y	Y	P	S	Q
50	260	270	280	290	300
	TTTGATCACACTAATAAGGGCACCTTCTTGCCTTATATTATCCATCCCA				
	F	D	H	T	N
	K	G	T	F	L
	T	R	L	R	L
	Y	Y	P	S	Q
	310	320	330	340	350
	AGATAATGATGCCCTTGACACCCCTTGGATCCAAATAAGAATATTTT				
	D	N	D	R	L
	T	L	W	I	P
	L	W	I	N	K
	W	I	P	E	Y
	F	W	S	F	W
55	360	370	380	390	400
	GGGGTCTTAGCAAATTCTTGGAACACACTGGCTTATGGCAACATTTG				
	G	L	S	K	F
	L	G	T	H	W
	W	L	M	G	N
	L	I	L		

	410	420	430	440	450
	AGGTTACTCTTGGTCAATGACAACCTCCTGCAAACGTGAATTCCCTCT				
	R L L F G S M T T P A N W N S P L				
5	460	470	480	490	500
	GAGGCCTGGTGAAAATATCCACTTGTGTTTTCTCATGGTCTGGGG				
	R P G E K Y P L V V F S H G L G A				
10	510	520	530	540	550
	CATTCAGGACACTTTATTCTGCTATTGGCATTGACCTGGCATCTCATGGG				
	F R T L Y S A I G I D L A S H G				
15	560	570	580	590	600
	TTTATAGITGCTGCTGTAGAACACAGAGATAGATCTGCATCTGCAACTTA				
	F I V A A V E H R D R S A S A T Y				
20	610	620	630	640	650
	CTATTTCAAGGACCAATCTGCTGCAGAAATAGGGGACAAGTCTGGCTCT				
	Y F K D Q S A A E I G D K S W L Y				
25	660	670	680	690	700
	ACCTTAGAACCCCTGAAACAAGAGGAGGAGACACATATACGAAATGAGCAG				
	L R T L K Q E E E T H I R N E Q				
30	710	720	730	740	750
	GTACGGCAAGAGCAAAAGAATGTTCCCAAGCTCTCAGTCTGATTCTGA				
	V R Q R A K E C S Q A L S L I L D				
35	760	770	780	790	800
	CATTGATCATGGAAAGCCAGTGAAGAATGCATTAGATTAAAGTTGATA				
	I D H G K P V K N A L D L K F D M				
40	810	820	830	840	850
	TGGAACAACTGAAGGACTCTATTGATAGGGAAAAAATAGCAGTAATTGGA				
	E Q L K D S I D R E K I A V I G				
45	860	870	880	890	900
	CATTCTTGGTGGAGCAACGGTTATTCAAGACTCTTAGTGAAGATCAGAG				
	H S F G G A T V I Q T L S E D Q R				
50	910	920	930	940	950
	ATTCAGATGTGGTATTGCCCTGGATGCATGGATGTTCCACTGGGTGATG				
	F R C G I A L D A W M F P L G D E				
55	960	970	980	990	1000
	AAGTATATTCCAGAATTCCCTCAGCCCCCTTTTATCAACTCTGAATAT				
	V Y S R I P Q P L F F I N S E Y				
60	1010	1020	1030	1040	1050
	TTCCAATATCCTGCTAATATCATAAAAATGAAAAAAATGCTACTCACCTGA				
	F Q Y P A N I I K M K K C Y S P D				
65	1060	1070	1080	1090	1100
	TAAAGAAAGAAAGATGATTACAATCAGGGGTTCAAGTCACCAGAAATTG				
	K E R K M I T I R G S V H Q N F A				

	1110	1120	1130	1140	1150
	CTGACTTCACTTTGCAACTGGCAAAATAATTGGACACATGCTCAAATTA				
	D	F	T	F	A
	A	T	G	K	I
	I	I	G	H	M
			L	K	L
5					
	1160	1170	1180	1190	1200
	AAGGGAGACATAGATTCAAATGCAGCTATTGATCTTAGCAACAAAGCTTC				
	K	G	D	I	D
	S	N	A	A	I
	A	I	D	L	S
			N	K	A
10					
	1210	1220	1230	1240	1250
	ATTAGCATTCTTACAAAAGCATTAGGACTTCATAAAAGATTTGATCAGT				
	L	A	F	L	Q
	K	K	Q	K	H
	H	L	G	L	L
			H	K	K
			D	F	D
			Q	W	
15					
	1260	1270	1280	1290	1300
	GGGACTGCTTGATTGAAGGGAGATGATGAGAACATCTTATTCCAGGGACCAAC				
	D	C	L	I	E
	G	D	D	E	G
	D	E	N	L	I
			P	G	T
			N	N	N
20					
	1310	1320	1330	1340	1350
	ATTAACACAACCAATCAACACATCATGTTACAGAACTCTTCAGGAATAGA				
	I	N	T	T	N
	T	Q	H	I	M
	N	H	I	M	L
			Q	N	S
			S	S	G
			G	I	E
25					
	1360				
	GAAATACAATT				
	K	Y	N	.	

SEQ. ID. No: 10 -Peptide 5

30 -Q-Y-I-N-P-V-A-

SEQ. ID. No: 11 -Peptide 6

-M-I-T-I-R-G-S-V-H-Q-N-F-A-D-F-T-F-A-T-G-

CLAIMS:

1. The enzyme Lp-PLA₂ in purified form
- 5 2. The enzyme Lp-PLA₂ according to claim 1 characterised by one or more partial peptide sequences selected from SEQ ID NOs:1, 2, 3, 4, 10 and 11 and/or by having a molecular weight of at least 45kDa.
- 10 3. The enzyme Lp-PLA₂ according to claim 1 or 2 having a molecular weight of 45kDa.
4. The enzyme Lp-PLA₂ according to claim 1 or 2 having a molecular weight of 45-50kDa.
- 15 5. The enzyme Lp-PLA₂ according to claim 4 having a molecular weight of 45-47kDa
6. The enzyme Lp-PLA₂ according to claim 5 having a molecular weight of 46-47kDa
- 20 7. The enzyme Lp-PLA₂ according to claim 1 characterised by the partial peptide sequence corresponding to residues 271 to 441 of SEQ ID NO:9.
8. The enzyme Lp-PLA₂ according to claim 1 having the sequence given in SEQ 25 ID NO:9, or an enzyme or fragment thereof having Lp-PLA₂ activity and substantially homologous to SEQ ID NO:9.
9. An enzyme fragment selected from SEQ.ID NOs:1, 2, 3, 4, 10 and 11.
- 30 10. An isolated nucleic acid molecule encoding Lp-PLA₂ or an antisense analogue thereof.
11. An isolated nucleic acid molecule encoding the enzyme or fragment of any one of claims 1 to 9 or an antisense analogue thereof.
- 35 12. An isolated nucleic acid molecule according to claim 10 comprising the sequence corresponding to:
bases 1-389 of SEQ.ID NO:5;
bases 1-304 of SEQ.ID NO:6;
40 bases 1-278 of SEQ.ID NO:7; or
SEQ.ID NO:8;
or an antisense analogue thereof.
13. An isolated nucleic acid molecule according to claim 10 comprising the sequence corresponding to bases 848 to 1361 of SEQ ID NO:9 or an antisense analogue thereof.

14. An isolated nucleic acid molecule according to claim 10 consisting of bases 1 to 1361 or 38 to 1361 of SEQ.ID NO:9 or a nucleic acid molecule encoding an enzyme having Lp-PLA₂ activity and substantially homologous to said isolated molecule, or antisense analogues thereof.
5
15. A recombinant vector comprising the nucleic acid molecule of any one of claims 10 to 14.
- 10 16. A host cell comprising the molecule of any one of claims 10 to 14.
17. The use of an inhibitor of the enzyme Lp-PLA₂ in therapy.
18. The use of an inhibitor of Lp-PLA₂ in the treatment of atherosclerosis
15
19. A method of diagnosis of a patients susceptibility to atherosclerosis which comprises taking a sample of blood from the patient and analysing said sample for the presence of the enzyme Lp-PLA₂.
- 20 20. The method according to claim 19 in which the analysis of said sample comprises assaying the sample for enzyme activity.
21. The method according to claim 19 in which the analysis of said sample comprises assaying the sample for protein content using polyclonal or monoclonal antibodies raised against the enzyme.
25
22. A polyclonal antibody raised against the purified Lp-PLA₂ enzyme as claimed in any of claims 1 to 8.
- 30 23. A monoclonal antibody raised against the purified Lp-PLA₂ enzyme as claimed in any of claims 1 to 8.
24. A method of screening compounds to identify those compounds which inhibit the enzyme comprising contacting isolated enzyme Lp-PLA₂ with a test compound
35 and measuring the rate of turnover of an enzyme substrate as compared with the rate of turnover in the absence of test compound.




Fig.1 Compound 4 inhibits copper (5µM) - stimulated LDL (150µg/ml) oxidation.

FIGURE 2:

Lanes 2, 4 and 6 contain adjacent fractions of purified native Lp-PLA2. Lanes 1, 3 and 5 are fractions 2, 4 and 6 respectively after N-deglycosylation.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 94/01374

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5	C12N15/55	C12N15/70	C12N9/18	A61K37/64	C12N1/21
	C12P21/08	G01N33/573	C12Q1/44		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C12N A61K G01N C12P C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>EP,A,0 509 719 (ELI LILLY AND COMPANY) 21 October 1992</p> <p>see page 2, line 26 - line 41 see page 3, line 3 - line 9 see page 5, line 4 - line 13 ---</p>	1,10, 15-17, 22,24
A	<p>WO,A,89 09818 (BIOGEN, INC.) 19 October 1989</p> <p>see page 8, line 13 - line 24 see page 13, line 30 - page 14, line 25 see page 15, line 8 - page 16, line 5 see page 16, line 19 - line 23 ---</p>	1,10,15, 16,22
A	<p>EP,A,0 359 425 (SHIONOGI & CO. LTD.) 21 March 1990</p> <p>see page 2, line 46 - page 3, line 13 -----</p>	1,10,15, 16

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *'A' document defining the general state of the art which is not considered to be of particular relevance
- *'B' earlier document but published on or after the international filing date
- *'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *'O' document referring to an oral disclosure, use, exhibition or other means
- *'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

'&' document member of the same patent family

2 Date of the actual completion of the international search

Date of mailing of the international search report

29 September 1994

18. 10. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentiaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Montero Lopez, B

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB94/01374

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 17-18 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the composition.

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 94/01374

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0509719	21-10-92	JP-A-	5103677	27-04-93
		US-A-	5328842	12-07-94
WO-A-8909818	19-10-89	AU-A-	3548289	03-11-89
		JP-T-	3503843	29-08-91
EP-A-0359425	21-03-90	JP-A-	2065781	06-03-90
		AU-B-	617209	21-11-91
		AU-A-	4005489	01-03-90